Maryam Tabatabai, PharmD, vice president of clinical information, and Carole Kerzic, RPh, drug information pharmacist, share more about glucagon-like peptide-1 (GLP-1) receptor agonists in the drug...

New clinical publication from Prime Therapeutics explores the latest insights for GLP-1s, including trends in spend, drugs in the pipeline, management strategies and more

In the latest episode of the “Pharmacy Friends” podcast, join health outcomes experts for a discussion about Prime’s industry-leading research into persistence and adherence of glucagon-like...

Novo Nordisk’s semaglutide (Wegovy) recently received a U.S. Food and Drug Administration (FDA) accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH), the first...

New resource page offers the latest GLP-1 insights, research and perspectives

New report details the latest on GLP-1s

Following real-world analysis of GLP-1 drugs for weight loss, Prime/Magellan Rx releases new video about GLP-1 research

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

In this second of a two-part episode of the Pharmacy Friends podcast, industry experts discuss clinical evidence, drug information and appropriate patient selection for GLP-1 use